• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    9/1/22 5:40:07 PM ET
    $ADIL
    $BGXX
    $BTX
    $CEMI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • SenesTech (NASDAQ:SNES) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
    • Chembio Diagnostics (NASDAQ:CEMI) stock rose 14.06% to $0.73. Chembio Diagnostics's trading volume hit 558.2K shares by close, accounting for 49.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $22.0 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) shares rose 10.51% to $3.68. The company's market cap stands at $140.0 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares rose 8.96% to $0.83. The company's market cap stands at $13.8 million.
    • Brooklyn (NASDAQ:BTX) stock moved upwards by 8.94% to $0.41. At the close, Brooklyn's trading volume reached 89.3K shares. This is 15.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $24.3 million.
    • Biote (NASDAQ:BTMD) shares moved upwards by 8.61% to $4.79. The market value of their outstanding shares is at $36.2 million.

    Losers

    • Venus Concept (NASDAQ:VERO) shares fell 9.7% to $0.32 during Thursday's after-market session. The company's market cap stands at $20.6 million.
    • GT Biopharma (NASDAQ:GTBP) stock decreased by 8.26% to $2.5. The market value of their outstanding shares is at $77.7 million.
    • Bright Green (NASDAQ:BGXX) stock declined by 7.75% to $1.43. At the close, Bright Green's trading volume reached 11.6 million shares. This is 1177.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $228.5 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock fell 7.03% to $0.49. The market value of their outstanding shares is at $12.5 million.
    • Comera Life Sciences (NASDAQ:CMRA) shares decreased by 6.43% to $2.04. This security traded at a volume of 1.2 million shares come close, making up 35.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $38.9 million.
    • Reviva Pharmaceuticals (NASDAQ:RVPH) stock decreased by 6.26% to $2.1. The company's market cap stands at $38.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $BGXX
    $BTX
    $CEMI

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    GT Biopharma Inc.
    $GTBP
    12/2/2024$11.00Buy
    ROTH MKM
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    BlackRock Technology and Private Equity Term Trust
    $BTX
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

    CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warrants to purchase u

    3/18/26 10:34:16 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

    CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the of

    3/18/26 4:10:29 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on GT Biopharma with a new price target

    ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

    12/2/24 10:00:20 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADIL
    $BGXX
    $BTX
    $CEMI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    3/18/26 5:23:43 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form 424B5 filed by Reviva Pharmaceuticals Holdings Inc.

    424B5 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

    3/18/26 4:09:14 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form N-CEN filed by BlackRock Technology and Private Equity Term Trust

    N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

    3/13/26 4:12:15 PM ET
    $BTX

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADIL
    $BGXX
    $BTX
    $CEMI
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

    Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. The declarations have moved from monthly to quarterly to provide additional visibility on upcoming distributions. The funds will continue to pay monthly distributions. Municipal Funds: Certain Municipal Funds involved in upcoming mergers or reorganizations announced distributions separately. Distribution Month             Ex- & Record Date             Payable Date April             April 15, 2026             May 1, 2026 May             May 15, 2026             June 1, 2026 June             June 15, 2026            

    2/27/26 4:31:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable